SGLT2 inhibitor/GLP-1 receptor agonists as first step monotherapy—evidence and implications

被引：0
|
作者：
Anil Pareek
Ravi T. Mehta
Shruti Dharmadhikari
机构：
[1] Ipca Laboratories Limited,Medical Affairs and Clinical Research Department
来源：
International Journal of Diabetes in Developing Countries | 2020年 / 40卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：636 / 637
页数：1
相关论文
共 50 条
  • [31] Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Pedro Cardoso
    Katie G. Young
    Anand T. N. Nair
    Rhian Hopkins
    Andrew P. McGovern
    Eram Haider
    Piyumanga Karunaratne
    Louise Donnelly
    Bilal A. Mateen
    Naveed Sattar
    Rury R. Holman
    Jack Bowden
    Andrew T. Hattersley
    Ewan R. Pearson
    Angus G. Jones
    Beverley M. Shields
    Trevelyan J. McKinley
    John M. Dennis
    [J]. Diabetologia, 2024, 67 : 822 - 836
  • [32] Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
    Scheen, Andre J.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 143 : 88 - 100
  • [33] Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk
    Marx, Niko
    Grant, Peter J.
    Cosentino, Francesco
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 (02) : 329 - 330
  • [34] SGLT2 inhibitor and GLP-1 analogue combination therapy in Type 2 diabetes
    Bashir, J.
    Stephens, J.
    Anderson, R.
    Hayes, J.
    Elamin, O.
    Lloyd, A.
    [J]. DIABETIC MEDICINE, 2016, 33 : 165 - 166
  • [35] Global Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: Results from DISCOVER
    Arnold, Suzanne V.
    Tang, Fengming
    Cooper, Andrew
    Chen, Hungta
    Gomes, Marilia B.
    Rathmann, Wolfgang
    Shimomura, Iichiro
    Vora, Jiten
    Watada, Hirotaka
    Khunti, Kamlesh
    Kosiborod, Mikhail N.
    [J]. DIABETES, 2021, 70
  • [36] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Compared with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina M.
    Marsolo, Keith
    Bosworth, Hayden B.
    Pagidipati, Neha
    [J]. DIABETES, 2024, 73
  • [37] Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Cardoso, Pedro
    Young, Katie G.
    Nair, Anand T. N.
    Hopkins, Rhian
    Mcgovern, Andrew P.
    Haider, Eram
    Karunaratne, Piyumanga
    Donnelly, Louise
    Mateen, Bilal A.
    Sattar, Naveed
    Holman, Rury R.
    Bowden, Jack
    Hattersley, Andrew T.
    Pearson, Ewan R.
    Jones, Angus G.
    Shields, Beverley M.
    McKinley, Trevelyan J.
    Dennis, John M.
    [J]. DIABETOLOGIA, 2024, 67 (05) : 822 - 836
  • [38] SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study
    Al-Mashhadi, Zheer Kejlberg
    Viggers, Rikke
    Starup-Linde, Jakob
    Vestergaard, Peter
    Gregersen, Soren
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [39] Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists
    Scott Cohen
    Hillel Sternlicht
    George L. Bakris
    [J]. Current Diabetes Reports, 2022, 22 : 213 - 218
  • [40] Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists
    Cohen, Scott
    Sternlicht, Hillel
    Bakris, George L.
    [J]. CURRENT DIABETES REPORTS, 2022, 22 (05) : 213 - 218
12345